Vivos Therapeutics (NASDAQ:VVOS) Trading Up 24.6% – What’s Next?

Vivos Therapeutics, Inc. (NASDAQ:VVOS)’s stock price shot up 24.6% on Friday . The stock traded as high as $2.57 and last traded at $2.53. 401,920 shares changed hands during trading, an increase of 290% from the average session volume of 103,058 shares. The stock had previously closed at $2.03.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on VVOS. HC Wainwright initiated coverage on shares of Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective on the stock. Zacks Research raised Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, Ascendiant Capital Markets cut their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, December 3rd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.92.

Vivos Therapeutics Stock Performance

The company has a market capitalization of $22.74 million, a P/E ratio of -1.43 and a beta of 6.89. The business has a 50 day moving average of $2.25 and a 200 day moving average of $3.43. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. The business had revenue of $6.78 million for the quarter, compared to analysts’ expectations of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. On average, sell-side analysts predict that Vivos Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Hedge Funds Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VVOS. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics during the 2nd quarter valued at about $65,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics during the second quarter worth approximately $220,000. Finally, Connective Capital Management LLC purchased a new stake in Vivos Therapeutics during the third quarter valued at approximately $620,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.